IONIQ Sciences

IONIQ Sciences is developing an advanced multi-cancer early detection screening technology that has the potential to expand the treatment window, significantly improve survival rates, and reduce healthcare costs. IONIQ Sciences combines its Electrical Impedance Analysis (EIA) or bioimpedance technology with Artificial Intelligence (AI). The first product from IONIQ Sciences to utilize its proprietary analytics platform, the IONIQ ProLung Test™ for lung cancer, has been designated as a Breakthrough Device by the U.S. FDA.